Skip to content
Peptigraph home

Peptides for Cholesterol

The peptides people most often research for cholesterol, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
6
With human trials
5
FDA approved (any use)
4
Showing 6 peptides · ordered by search interest for this goal
  1. TesamorelinGHRH analogHuman RCT evidence, 4 of 4Clinical infectious diseases 2012, PMID 22495074Human13Animal0Summarised6FDA approved (Egrifta)For cholesterolOverview
  2. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444Human100Animal10Summarised7FDA approved (Mounjaro, Zepbound)For cholesterolOverview
  3. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Diabetes, obesity & metabolism 2026, PMID 42608321Human7Animal4Summarised3Investigational · phase 3For cholesterolOverview
  4. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4American heart journal 2025, PMID 40345413Human226Animal38Summarised8FDA approved (Ozempic, Wegovy, Rybelsus)For cholesterolOverview
  5. HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4Clinical endocrinology 1998, PMID 10197085Human622Animal61Summarised4FDA approved (prescription only)For cholesterolOverview
  6. IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for cholesterolPubMed search, 11 Oct 2026Human1Animal0Summarised0Not FDA approved · research chemicalOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

What cholesterol is

MedlinePlus says too much cholesterol in the blood can combine with other substances to form plaque on artery walls.[9]

It names an unhealthy lifestyle as the most common cause of high cholesterol.[9]

Lipid results are secondary outcomes of other trials

Semaglutide shows 226 human-only papers and 38 animal papers for cholesterol and tirzepatide 100 and 10, whereas ipamorelin has 1 human-only paper.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); tesamorelin human only 13, animal only 0, rct 7; tirzepatide human only 100, animal only 10, rct 18; retatrutide human only 7, animal only 4, rct 0; semaglutide human only 226, animal only 38, rct 25; hgh human only 622, animal only 61, rct 115; ipamorelin human only 1, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

In a tirzepatide meta-analysis, HDL cholesterol rose while LDL cholesterol and triglycerides fell.[10]

A retatrutide meta-analysis found no significant effect on HDL-C (weighted mean difference -0.01 mg/dL, p = 0.98).[11]

In a 52-week tesamorelin extension, visceral fat was down 18% from baseline and triglycerides down 51 mg/dl.[12]

A growth hormone review found total and LDL cholesterol decreased but triglycerides and HDL did not change.[13]

At 6 months, a growth hormone trial found no lipid difference from placebo.[5]

Common questions

Is there a peptide that lowers cholesterol?

Tirzepatide has pooled trial data: a meta-analysis of randomized tirzepatide trials found total cholesterol fell by a median of 3.76% at 5 mg, 4.63% at 10 mg and 5.93% at 15 mg weekly, with LDL cholesterol and triglycerides down and HDL cholesterol up.[10]

Is there a best peptide for cholesterol?

The cited sources do not rank peptides for lipids; the retatrutide meta-analysis found no significant effect on HDL-C.[11]

Do peptides for cholesterol replace diet?

NIH says the most common cause of high cholesterol is an unhealthy lifestyle.[9]

Sources

  1. 1Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
  2. 2Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  3. 3Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  4. 4Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
  5. 5HDL-cholesterol reductions associated with adult growth hormone replacement.Clinical endocrinology · 1998PMID 10197085Accessed 2 Oct 2026
  6. 6PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  9. 9Official web pageOfficial web page · web page
  10. 10Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.Diabetes, obesity & metabolism · 2023PMID 37700437Accessed 2 Oct 2026
  11. 11Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026
  12. 12Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  13. 13GH replacement therapy in elderly GH-deficient patients: a systematic review.European journal of endocrinology · 2011PMID 21339335Accessed 2 Oct 2026

Found an error? Report a correction.